Effects of linagliptin vs glimepiride stratified by prior insulin secretagogue use in the cardiovascular outcome study of linagliptin versus glimepiride in type 2 diabetes (CAROLINA) trial

被引：0
|
作者：
McGuire, D. K. [1 ]
Rosenstock, J. [2 ]
Johansen, O. E. [3 ]
Zinman, B. J. [4 ]
Khunti, K. [5 ]
Mattheus, M. [6 ]
Lund, S. S. [3 ]
Espeland, M. A. [7 ]
Marx, N. [8 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[2] Dallas Diabet Res Ctr Med City, Dallas, TX USA
[3] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[4] Univ Hlth Network, Lunenfeld Tanenbaum Res Inst, Mt Sinai Hosp, Toronto, ON, Canada
[5] Univ Leicester, Leicester, Leics, England
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[7] Wake Forest Univ, Winston Salem, NC 27101 USA
[8] RWTH Univ Hosp Aachen, Aachen, Germany
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3356 / 3356
页数：1
相关论文
共 50 条
  • [41] 4.6 Effects of Combined Therapy of Empagliflozin and Linagliptin Versus Metformin and Insulin Glargine on Blood Pressure and Vascular Function in Patients with Type 2 Diabetes
    Christian Ott
    Susanne Jung
    Agnes Bosch
    Dennis Kannenkeril
    Kristina Striepe
    Roland Schmieder
    Artery Research, 2019, 25 (Suppl 1) : S35 - S35
  • [42] Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease
    Marx, Nikolaus
    Mcguire, Darren K.
    Johansen, Odd Erik
    Rosenstock, Julio
    Kahn, Steven E.
    Cooper, Mark E.
    Toto, Robert D.
    Wanner, Christoph
    Pfarr, Egon
    Schnaidt, Sven
    George, Jyothis
    Von Eynatten, Maximilian
    Perkovic, Vlado
    Zinman, Bernard
    Alexander, John H.
    DIABETES, 2019, 68
  • [43] Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study
    Liu, S-C
    Lee, C-C
    Chuang, S-M
    Sun, F-J
    Zeng, Y-H
    DIABETES & METABOLISM, 2021, 47 (03)
  • [44] Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi-heart study
    Chung, Seung Min
    Moon, Jun Sung
    Hong, Jun Hwa
    Hwang, In-Chang
    Lim, Soo
    DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2181 - 2190
  • [45] Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial
    Sezai, Akira
    Tanaka, Atsushi
    Imai, Takumi
    Kida, Keisuke
    Sekino, Hisakuni
    Murohara, Toyoaki
    Sata, Masataka
    Suzuki, Norio
    Node, Koichi
    BIOMEDICINES, 2022, 10 (07)
  • [46] A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients With Type 2 Diabetes in Long-term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial
    Umpierrez, Guillermo E.
    Cardona, Saumeth
    Chachkhiani, David
    Fayfman, Maya
    Saiyed, Sahebi
    Wang, Heqiong
    Vellanki, Priyathama
    Haw, J. Sonya
    Olson, Darin E.
    Pasquel, Francisco J.
    Johnson, Theodore M.
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2018, 19 (05) : 399 - +
  • [47] First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease
    Marx, N.
    McGuire, D. K.
    Johansen, O.
    Rosenstock, J.
    Kahn, S. E.
    Cooper, M. E.
    Toto, R.
    Wanner, C.
    Pfarr, E.
    Schnaidt, S. Y.
    George, J. T.
    Von Eynatten, M.
    Perkovic, V.
    Zinman, B.
    Alexander, J. A.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3877 - 3877
  • [48] Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial
    Laakso, Markku
    Rosenstock, Julio
    Groop, Per-Henrik
    Barnett, Anthony H.
    Gallwitz, Baptist
    Hehnke, Uwe
    Tamminen, Ilkka
    Patel, Sanjay
    von Eynatten, Maximilian
    Woerle, Hans-Juergen
    DIABETES CARE, 2015, 38 (02) : E15 - E17
  • [49] Comparison of the effects of glimepiride vs. pioglitazone plus nateglinide therapy on insulin sensitivity and ectopic fat storage in well-controlled type 2 diabetes
    Brehm, A
    Bernroider, E
    Krssak, M
    Anderwald, C
    Krebs, M
    Schmid, AI
    Nowotny, P
    Roden, M
    DIABETES, 2005, 54 : A528 - A528
  • [50] Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes A ≥ 52-week randomized, double-blind study
    Yki-Jarvinen, Hannele
    Rosenstock, Julio
    Duran-Garcia, Santiago
    Pinnetti, Sabine
    Bhattacharya, Sudipta
    Thiemann, Sandra
    Patel, Sanjay
    Woerle, Hans-Juergen
    DIABETES CARE, 2013, 36 (12) : 3875 - 3881
12345